Hamlet Pharma partners with European CRO, Neox Clinical Research
Hamlet Pharma has signed an agreement with Neox Clinical Research to advance the company’s Phase II bladder cancer study in Prague, Czech Republic.
The contract research organization (CRO), which focuses on Phase II and Phase III clinical trials in central Europe, will be responsible for monitoring the study and ensuring compliance with European and US FDA standards. Additionally, Neox will be responsible for data management and Pharmacovigilance.
Patients will be recruited from a clinic at the University Hospital, with which Neox has previously worked.
According to the Hamlet Pharma's release, Neox will also help communicate with local authorities and ethics committees.
The company did not provide any additional comment on the agreement.
